Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC, (PER®) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Eisai, Inc., and Exelixis, Inc.

Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular Carcinoma

Release Date: August 30, 2018
Expiration Date: August 30, 2019
Media: Internet - based

Activity Overview

Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular Carcinoma, is an online activity based on the live symposium held adjunct to the annual oncology meeting in Chicago.
Historically, hepatocellular carcinoma (HCC) has been associated with poor outcomes, in large part due to the few effective treatment options available to patients who are ineligible for curative therapy. However, recent approvals and emerging strategies for HCC are transforming patient care and improving patient outcomes. Within this online interactive activity, 2 internationally renowned experts in HCC will provide you with their insights on a number of clinically important questions regarding immunotherapy and other targeted therapies, treatment selection and sequencing, and adverse event management.
During this activity, you will learn about:
  • The biology and mechanisms of action of newer targeted agents for HCC
  • Key clinical trial data that are changing how patients with HCC are treated
  • Integrating new therapeutic options into your care plans for patients with HCC

Acknowledgment of Commercial Support

This activity is supported by educational grants from Eisai, Inc., and Exelixis, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with hepatocellular carcinoma (HCC). Nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with HCC also are invited to participate.

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

  1. Describe how the natural history of HCC is evolving, and the implications of these changes for patients and the practitioners who manage patients with these tumors
  2. Explain the biology and mechanistic rationale that underlie recent targeted drug development in HCC
  3. Evaluate efficacy and safety outcomes from practice-changing clinical trials conducted in patients with HCC
  4. Apply recent evidence and patient characteristics to inform optimized sequencing decisions in the management of patients with HCC


Alan P. Venook, MD, FASCO
Madden Family Distinguished Professor in Medical Oncology and Translational Research
Shorenstein Associate Director, Program Development
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, CA

Disclosure: Grant/Research Support: Genentech, Roche; Consultant: Halozyme


Anthony El-Khoueiry, MD
Associate Professor of Clinical Medicine
Norris Cancer Center CISO Chair
Keck School of Medicine
University of Southern California
Los Angeles, CA

Disclosure: Dr. El-Khoueiry reports no relevant financial relationships with commercial interests to disclose.

Jordi Bruix, MD, PhD
Professor of Medicine
University of Barcelona
Director, Barcelona Clinic Liver Cancer (BCLC) Group
Liver Unit at the Hospital Clinic
Barcelona, Spain

Disclosure: Grant/Research Support: Bayer; Consultant: Daiichi Sankyo, ArQule, Bayer, AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Lilly, Kowa, Novartis, Roche, Onxeo, Terumo, Sirtex; Advisory Boards: Bayer, AbbVie, Bristol-Myers Squibb, Novartis, Roche, Onxeo, Terumo, Sirtex, BTG

Ghassan K. Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosure: Grant/Research Support: Agios, Array, AstraZeneca, Bayer, BMS, Casi, Celgene, Exelixis, Genentech, Incyte, Lilly, MabVax, MedImmune, Momenta, Novartis, OncoMed Pharmaceuticals, Roche; Consultant: Agios, Amgen, Antengene, Aptus, Aslan, Astellas, AstraZeneca, Bayer, BMS, Boston Scientific, CARsgen, Celgene, Casi, CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Gilead, Halozyme, Inovio, Ipsen, Merck, Onxeo, PCI Biotech, Roche, Sanofi, Servier, Silenseed, Sillajen, Sirtex, Yakult

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Become a Member

Forgot Password?
Calendar of Events
Filter By